Evolocumab for Patients Without Known Atherosclerosis and With Diabetes
https://jamanetwork.com/journals/jama/fullarticle/2847162
This prespecified subgroup analysis of the VESALIUS-CV multinational randomized clinical trial assesses whether evolocumab could prevent a first major cardiovascular event in adult patients without known significant atherosclerosis and with diabetes.
https://jamanetwork.com/journals/jama/fullarticle/2847162
This prespecified subgroup analysis of the VESALIUS-CV multinational randomized clinical trial assesses whether evolocumab could prevent a first major cardiovascular event in adult patients without known significant atherosclerosis and with diabetes.
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2847161
This study evaluated whether evolocumab prevents first major cardiovascular events in high-risk patients without known significant atherosclerosis and with diabetes.
https://jamanetwork.com/journals/jama/fullarticle/2847161
This study evaluated whether evolocumab prevents first major cardiovascular events in high-risk patients without known significant atherosclerosis and with diabetes.
Extended Low-Dose Apixaban and Superficial Vein Thrombosis
https://jamanetwork.com/journals/jamacardiology/fullarticle/2847054
This post hoc analysis of the Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism (HI-PRO) randomized clinical trial investigates the impact of extended low-dose apixaban on symptomatic superficial vein thrombosis events in patients with provoked venous thromboembolism and enduring risk factors.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2847054
This post hoc analysis of the Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism (HI-PRO) randomized clinical trial investigates the impact of extended low-dose apixaban on symptomatic superficial vein thrombosis events in patients with provoked venous thromboembolism and enduring risk factors.
sNfL and Cardiovascular Risk in AF
https://jamanetwork.com/journals/jamacardiology/fullarticle/2847053
This cohort study evaluates the association between serum neurofilament light chain and cardiovascular outcomes in atrial fibrillation.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2847053
This cohort study evaluates the association between serum neurofilament light chain and cardiovascular outcomes in atrial fibrillation.
Signal, Speculation, and Standards of Proof in Iatrogenic AD
https://jamanetwork.com/journals/jamaneurology/fullarticle/2847010
Neurodegenerative diseases caused by protein misfolding (eg, Alzheimer disease [AD], frontotemporal lobar degeneration, Parkinson disease) share many similarities with prion diseases. All demonstrate template-directed protein misfolding and propagation in vivo. However, with 1 exception, they have not exhibited interindividual or zoonotic transmission as observed in iatrogenic Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease, respectively. An important unresolved question is whether other proteinopathies are transmissible between individuals, and if so, their potential impact on public health. To address these concerns, several prion centers have re-assessed cases of iatrogenic Creutzfeldt-Jakob disease due to cadaver-derived human growth hormone (c-hGH) and dura mater grafts. Although amyloid β (Aβ) plaques and cerebral amyloid angiopathy were commonly seen, tau pathology necessary for a diagnosis of AD was not. Thus, while there is adequate evidence that cerebral amyloid angiopathy may be acquired through iatrogenic mechanisms, iatrogenic transmission of AD pathology remained speculative.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2847010
Neurodegenerative diseases caused by protein misfolding (eg, Alzheimer disease [AD], frontotemporal lobar degeneration, Parkinson disease) share many similarities with prion diseases. All demonstrate template-directed protein misfolding and propagation in vivo. However, with 1 exception, they have not exhibited interindividual or zoonotic transmission as observed in iatrogenic Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease, respectively. An important unresolved question is whether other proteinopathies are transmissible between individuals, and if so, their potential impact on public health. To address these concerns, several prion centers have re-assessed cases of iatrogenic Creutzfeldt-Jakob disease due to cadaver-derived human growth hormone (c-hGH) and dura mater grafts. Although amyloid β (Aβ) plaques and cerebral amyloid angiopathy were commonly seen, tau pathology necessary for a diagnosis of AD was not. Thus, while there is adequate evidence that cerebral amyloid angiopathy may be acquired through iatrogenic mechanisms, iatrogenic transmission of AD pathology remained speculative.
High-Level Alzheimer Disease Neuropathological Change Following Iatrogenic Exposure
https://jamanetwork.com/journals/jamaneurology/fullarticle/2847009
This case series describes the clinical and postmortem findings in iatrogenic Alzheimer disease.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2847009
This case series describes the clinical and postmortem findings in iatrogenic Alzheimer disease.
Early vs Delayed Extubation After Thrombectomy for Acute Ischemic Stroke
https://jamanetwork.com/journals/jamaneurology/fullarticle/2847008
This randomized clinical trial compares 2 extubation time periods to evaluate whether early extubation (<6 hours) compared with delayed extubation (6-12 hours) improves 90-day functional outcomes for patients who had successful thrombectomy under general anesthesia.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2847008
This randomized clinical trial compares 2 extubation time periods to evaluate whether early extubation (<6 hours) compared with delayed extubation (6-12 hours) improves 90-day functional outcomes for patients who had successful thrombectomy under general anesthesia.
The Self-Test
https://jamanetwork.com/journals/jamaneurology/fullarticle/2847007
This essay describes the author’s experience with delirium and lessons gained from the vulnerability it brought.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2847007
This essay describes the author’s experience with delirium and lessons gained from the vulnerability it brought.
Intensive Chemoprophylaxis for Nursing Home Influenza Outbreaks
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846974
Influenza outbreaks are common and lead to morbidity in nursing home (NH) residents. To limit transmission, clinical guidelines from the US Centers for Disease Control and Prevention and the Infectious Diseases Society of America recommend prompt oseltamivir chemoprophylaxis for all exposed residents, even if asymptomatic. However, whether there is a threshold of proportion of residents who should receive postexposure prophylaxis to reduce serious complications such as hospitalization has not been studied. Of course, a randomized clinical trial (ideally a cluster-randomized trial) would be most desirable. However, conducting a cluster-randomized trial to answer this question would be logistically and ethically difficult as influenza outbreaks require an immediate response under evolving conditions that may outpace the implementation of such a study protocol for a known effective treatment.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846974
Influenza outbreaks are common and lead to morbidity in nursing home (NH) residents. To limit transmission, clinical guidelines from the US Centers for Disease Control and Prevention and the Infectious Diseases Society of America recommend prompt oseltamivir chemoprophylaxis for all exposed residents, even if asymptomatic. However, whether there is a threshold of proportion of residents who should receive postexposure prophylaxis to reduce serious complications such as hospitalization has not been studied. Of course, a randomized clinical trial (ideally a cluster-randomized trial) would be most desirable. However, conducting a cluster-randomized trial to answer this question would be logistically and ethically difficult as influenza outbreaks require an immediate response under evolving conditions that may outpace the implementation of such a study protocol for a known effective treatment.
❤2
Exchange Transfusion for Severe Babesiosis—Insights From a Multicenter Retrospective Analysis
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846973
Babesia microti is a tickborne intraerythrocytic parasite reported in at least 24 states across the US, with 1827 cases reported in 2020. Rising cases have been attributed to climate and weather changes across the country. Severe babesiosis, defined by high-grade parasitemia (>10%) and/or evidence of organ failure, is more common among older adults and individuals with comorbidities, immunosuppression, and asplenia. Current guidelines strongly recommend combination antiparasitic therapy; however, only in certain severe cases do they recommend exchange red blood cell transfusion (ET) because evidence of its benefit has been limited to small case series and low-quality observational studies.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846973
Babesia microti is a tickborne intraerythrocytic parasite reported in at least 24 states across the US, with 1827 cases reported in 2020. Rising cases have been attributed to climate and weather changes across the country. Severe babesiosis, defined by high-grade parasitemia (>10%) and/or evidence of organ failure, is more common among older adults and individuals with comorbidities, immunosuppression, and asplenia. Current guidelines strongly recommend combination antiparasitic therapy; however, only in certain severe cases do they recommend exchange red blood cell transfusion (ET) because evidence of its benefit has been limited to small case series and low-quality observational studies.
Practical Considerations for Improving Quality of Care for Hospitalized Patients With a Nondominant Language Preference
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846972
This Clinical Insights article discusses improving care quality for hospitalized patients who have a nondominant language preference.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846972
This Clinical Insights article discusses improving care quality for hospitalized patients who have a nondominant language preference.
❤2
Turnover and Burnout Among Family Physicians
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846971
This cross-sectional study explores the association between burnout and departure from the profession or move to a different practice among family physicians across the US.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846971
This cross-sectional study explores the association between burnout and departure from the profession or move to a different practice among family physicians across the US.
❤1
Reframing the Coronary Heart Disease Epidemic—The Role of Lead Exposure
https://jamanetwork.com/journals/jama/fullarticle/2846867
In the 1912 edition of The Principles and Practice of Medicine, William Osler described angina pectoris as serious but uncommon and observed that chronic lead intoxication played “an important role in the causation of arteriosclerosis.” Coronary thrombosis was not yet the defining illness of modern life. Within a few decades—during the age of industrial combustion and the rise of leaded gasoline—coronary heart disease became the leading cause of death in the US.
https://jamanetwork.com/journals/jama/fullarticle/2846867
In the 1912 edition of The Principles and Practice of Medicine, William Osler described angina pectoris as serious but uncommon and observed that chronic lead intoxication played “an important role in the causation of arteriosclerosis.” Coronary thrombosis was not yet the defining illness of modern life. Within a few decades—during the age of industrial combustion and the rise of leaded gasoline—coronary heart disease became the leading cause of death in the US.
Management of Acute Coronary Syndrome
https://jamanetwork.com/journals/jama/fullarticle/2846866
This JAMA Clinical Guidelines Synopsis summarizes the 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndrome.
https://jamanetwork.com/journals/jama/fullarticle/2846866
This JAMA Clinical Guidelines Synopsis summarizes the 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndrome.
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy
https://jamanetwork.com/journals/jamacardiology/fullarticle/2847055
This open-label extension of the ATTRibute-CM randomized clinical trial evaluates the long-term efficacy and safety of acoramidis through month 54.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2847055
This open-label extension of the ATTRibute-CM randomized clinical trial evaluates the long-term efficacy and safety of acoramidis through month 54.
Error in Figure
https://jamanetwork.com/journals/jama/fullarticle/2847279
In the Original Investigation titled “Emergency Department–Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial,” published in the March 17, 2026, issue of JAMA, the labels above the dot plot in Figure 2 were reversed. “Favors extended-release buprenorphine” applies to odds ratios greater than 1 and “Favors sublingual buprenorphine” applies to odds ratios less than 1. The legend of Figure 2 should have stated “Odds ratios greater than 1…indicate greater benefit for extended-release buprenorphine compared with sublingual buprenorphine.” This article was corrected online.
https://jamanetwork.com/journals/jama/fullarticle/2847279
In the Original Investigation titled “Emergency Department–Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial,” published in the March 17, 2026, issue of JAMA, the labels above the dot plot in Figure 2 were reversed. “Favors extended-release buprenorphine” applies to odds ratios greater than 1 and “Favors sublingual buprenorphine” applies to odds ratios less than 1. The legend of Figure 2 should have stated “Odds ratios greater than 1…indicate greater benefit for extended-release buprenorphine compared with sublingual buprenorphine.” This article was corrected online.
Title of Article Updated
https://jamanetwork.com/journals/jama/fullarticle/2847278
The title of the JAMA Clinical Guidelines Synopsis published online first on February 4, 2026, and in the March 3, 2026, issue of JAMA has been corrected to “Synopsis of ACOG Guideline on Management of Premenstrual Disorders.” This article was corrected online.
https://jamanetwork.com/journals/jama/fullarticle/2847278
The title of the JAMA Clinical Guidelines Synopsis published online first on February 4, 2026, and in the March 3, 2026, issue of JAMA has been corrected to “Synopsis of ACOG Guideline on Management of Premenstrual Disorders.” This article was corrected online.
Effectiveness of Ambient AI Scribes
https://jamanetwork.com/journals/jama/fullarticle/2847322
Ambient artificial intelligence (AI) scribes—technology tools that streamline documentation by listening in the background and drafting notes during clinical encounters—have rapidly moved from novelty into clinical infrastructure, motivated by a pressing goal: reducing the clerical burden that threatens workforce sustainability. While these tools have the potential to meaningfully advance parts of the quintuple aim—improving population outcomes, reducing costs, enhancing patient experience, addressing clinician burnout, and advancing health equity—the evidence supporting their ability to do so remains uneven across domains.
https://jamanetwork.com/journals/jama/fullarticle/2847322
Ambient artificial intelligence (AI) scribes—technology tools that streamline documentation by listening in the background and drafting notes during clinical encounters—have rapidly moved from novelty into clinical infrastructure, motivated by a pressing goal: reducing the clerical burden that threatens workforce sustainability. While these tools have the potential to meaningfully advance parts of the quintuple aim—improving population outcomes, reducing costs, enhancing patient experience, addressing clinician burnout, and advancing health equity—the evidence supporting their ability to do so remains uneven across domains.
Prioritizing Time from Diagnosis to Quadruple Therapy in Heart Failure Care
https://jamanetwork.com/journals/jamacardiology/fullarticle/2846903
Heart failure (HF) affects more than 7 million individuals in the US and carries a 5-year mortality rate of approximately 75% following hospitalization. To lower the risk of morbidity and mortality, guidelines recommend that patients with HF with reduced ejection fraction (HFrEF) receive quadruple therapy, consisting of β-blockers, angiotensin receptor–neprilysin inhibitors (ARNI), mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter-2 inhibitors (SGLT2i). Together, these 4 pillars of therapy are projected to reduce the relative risk of all-cause mortality by over 70%. Despite their proven benefits and commensurate class I guideline recommendation, uptake of these medications remains low with fewer than 1 in 6 medically eligible patients receiving quadruple therapy in a recent national registry analysis.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2846903
Heart failure (HF) affects more than 7 million individuals in the US and carries a 5-year mortality rate of approximately 75% following hospitalization. To lower the risk of morbidity and mortality, guidelines recommend that patients with HF with reduced ejection fraction (HFrEF) receive quadruple therapy, consisting of β-blockers, angiotensin receptor–neprilysin inhibitors (ARNI), mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter-2 inhibitors (SGLT2i). Together, these 4 pillars of therapy are projected to reduce the relative risk of all-cause mortality by over 70%. Despite their proven benefits and commensurate class I guideline recommendation, uptake of these medications remains low with fewer than 1 in 6 medically eligible patients receiving quadruple therapy in a recent national registry analysis.
Statin Eligibility According to Atherosclerotic Cardiovascular Disease Risk in the US
https://jamanetwork.com/journals/jamacardiology/fullarticle/2846902
To the Editor Khan and colleagues grapple with how to define statin eligibility in light of evolving cardiovascular disease (CVD) risk prediction algorithms. A conceptual problem lies in the approach Khan et al used to represent the underlying US population, as reflected in the National Health and Nutrition Examination Survey (NHANES) population survey. Using NHANES data, they identified a US population group who were not taking statins and also did not have a clinical characteristic, including diabetes, hypercholesterolemia, or prior atherosclerotic CVD (ASCVD), that clearly indicated the drug. Using data among this untreated group, representing 70.2 million US adults, they argue for the use of a threshold of at least 5% future 10-year risk of ASCVD, as estimated by the PREVENT equation, to identify the population who would achieve a substantial overall clinical benefit from use of statins.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2846902
To the Editor Khan and colleagues grapple with how to define statin eligibility in light of evolving cardiovascular disease (CVD) risk prediction algorithms. A conceptual problem lies in the approach Khan et al used to represent the underlying US population, as reflected in the National Health and Nutrition Examination Survey (NHANES) population survey. Using NHANES data, they identified a US population group who were not taking statins and also did not have a clinical characteristic, including diabetes, hypercholesterolemia, or prior atherosclerotic CVD (ASCVD), that clearly indicated the drug. Using data among this untreated group, representing 70.2 million US adults, they argue for the use of a threshold of at least 5% future 10-year risk of ASCVD, as estimated by the PREVENT equation, to identify the population who would achieve a substantial overall clinical benefit from use of statins.
❤2